Caesars Entertainment misses Q2 earnings expectations, shares edge lower
Needham reiterated its Buy rating and $48.00 price target on Establishment Labs Holdings Inc . (NASDAQ:ESTA), representing nearly 30% upside from the current price of $37.12, following the company’s investor day held Wednesday in New York City. According to InvestingPro data, analyst targets range from $38 to $62.
The medical technology company hosted three panels with plastic surgeon key opinion leaders at the event, focusing on breast augmentation and breast reconstruction procedures. These surgeons expressed highly positive views about Establishment Labs’ implants and procedures, predicting the company would gain significant U.S. market share within the next few years.
Establishment Labs management reaffirmed its 2025 financial guidance during the investor day. The company indicated its second-quarter U.S. revenue would likely exceed consensus estimates and noted it was not experiencing a slowdown in international markets.
Needham characterized Establishment Labs as "a rare small-cap med tech product cycle story" in its research note. The firm considers the company’s shares attractively valued given its growth potential.
The investor day featured detailed discussions with medical professionals who use Establishment Labs products, providing insights into the company’s market position and adoption rates among plastic surgeons specializing in breast procedures.
In other recent news, Establishment Labs Holdings Inc. reported its first-quarter revenue for 2025, which aligned with its earlier projections, while adjusted EBITDA surpassed consensus expectations. Despite a slowdown in revenue growth to 11% from the previous quarter’s 41%, the company maintained its revenue outlook for the year and noted a significant 91% increase in U.S. sales. Establishment Labs also experienced an improvement in gross margin, although the adjusted EBITDA margin saw a decline due to increased expenditures related to the U.S. market launch. In addition, Needham analysts upgraded the company’s stock rating from Hold to Buy, setting a price target of $48, citing the easing of trade tensions and potential growth from products like Mia and Preservé. Meanwhile, BTIG analysts initiated coverage with a Buy rating and a $62 price target, emphasizing the potential of the Motiva breast implants and anticipating positive adjusted EBITDA later in the year. Establishment Labs also announced the appointment of Peter Caldini as the new CEO, following his interim role since March, bringing extensive experience from previous leadership positions. The company continues to focus on innovative contributions to breast aesthetics, with upcoming product launches in the U.S. expected to drive expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.